Comparison of stress indices in gauging clinical activity in patients with inflammatory bowel disease

1992 ◽  
Vol 5 (4) ◽  
pp. 601-612 ◽  
Author(s):  
Linda C. Duffy ◽  
Maria A. Zielezny ◽  
James R. Marshall ◽  
Milton M. Weiser ◽  
James F. Phillips ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Activity ◽  
Stress Indices ◽  
Inflammatory Bowel

Vasoactive intestinal peptide as a laboratory supplement to clinical activity index in inflammatory bowel disease

1989 ◽  
Vol 34 (10) ◽  
pp. 1528-1535 ◽  
Author(s):  
Linda C. Duffy ◽  
Maria A. Zielezny ◽  
Marie Riepenhoff-Talty ◽  
Tim E. Byers ◽  
James Marshall ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Vasoactive Intestinal Peptide ◽  
Bowel Disease ◽  
Activity Index ◽  
Clinical Activity ◽  
Inflammatory Bowel

scholarly journals Quantitative contrast-enhanced ultrasound for monitoring vedolizumab therapy in inflammatory bowel disease patients: a pilot study

2018 ◽  
Vol 59 (10) ◽  
pp. 1149-1156 ◽  
Author(s):  
Ruediger S Goertz ◽  
Daniel Klett ◽  
Dane Wildner ◽  
Raja Atreya ◽  
Markus F Neurath ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Bowel Wall ◽  
Color Doppler ◽  
Response To Treatment ◽  
Clinical Activity ◽  
Contrast Enhanced Ultrasound ◽  
Software Analysis ◽  
Contrast Enhanced ◽  
Inflammatory Bowel

Background Microvascularization of the bowel wall can be visualized and quantified non-invasively by software-assisted analysis of derived time-intensity curves. Purpose To perform software-based quantification of bowel wall perfusion using quantitative contrast-enhanced ultrasound (CEUS) according to clinical response in patients with inflammatory bowel disease treated with vedolizumab. Material and Methods In a prospective study, in 18 out of 34 patients, high-frequency ultrasound of bowel wall thickness using color Doppler flow combined with CEUS was performed at baseline and after 14 weeks of treatment with vedolizumab. Clinical activity scores at week 14 were used to differentiate between responders and non-responders. CEUS parameters were calculated by software analysis of the video loops. Results Nine of 18 patients (11 with Crohn’s disease and seven with ulcerative colitis) showed response to treatment with vedolizumab. Overall, the responder group showed a significant decrease in the semi-quantitative color Doppler vascularization score. Amplitude-derived CEUS parameters of mural microvascularization such as peak enhancement or wash-in rate decreased in responders, in contrast with non-responders. Time-derived parameters remained stable or increased during treatment in all patients. Conclusion Analysis of bowel microvascularization by CEUS shows statistically significant changes in the wash-in-rate related to response of vedolizumab therapy.

scholarly journals Clinical activity is an independent risk factor of ischemic heart and cerebrovascular arterial disease in patients with inflammatory bowel disease

PLoS ONE ◽  
2018 ◽  
Vol 13 (8) ◽  
pp. e0201991 ◽  
Author(s):  
Guillaume Le Gall ◽  
Julien Kirchgesner ◽  
Mohamed Bejaoui ◽  
Cécilia Landman ◽  
Isabelle Nion-Larmurier ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Risk Factor ◽  
Bowel Disease ◽  
Independent Risk Factor ◽  
Arterial Disease ◽  
Ischemic Heart ◽  
Clinical Activity ◽  
Inflammatory Bowel

scholarly journals Correlating Gastrointestinal Histopathologic Changes to Clinical Disease Activity in Dogs With Idiopathic Inflammatory Bowel Disease

2018 ◽  
Vol 56 (3) ◽  
pp. 435-443 ◽  
Author(s):  
Karin A. Allenspach ◽  
Jonathan P. Mochel ◽  
Yingzhou Du ◽  
Simon L. Priestnall ◽  
Frances Moore ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Disease Activity ◽  
Bowel Disease ◽  
Scoring System ◽  
Activity Index ◽  
Clinical Disease ◽  
Clinical Activity ◽  
Clinical Disease Activity ◽  
Inflammatory Bowel ◽  
Histopathologic Changes

Prior studies have failed to detect a convincing association between histologic lesions of inflammation and clinical activity in dogs with inflammatory bowel disease (IBD). We hypothesized that use of a simplified histopathologic scoring system would improve the consistency of interpretation among pathologists when describing histologic lesions of gastrointestinal inflammation. Our aim was to evaluate the correlation of histopathologic changes to clinical activity in dogs with IBD using this new system. Forty-two dogs with IBD and 19 healthy control dogs were enrolled in this retrospective study. Endoscopic biopsies from the stomach, duodenum, ileum, and colon were independently scored by 8 pathologists. Clinical disease activity was scored using the Canine Inflammatory Bowel Disease Activity Index (CIBDAI) or the Canine Chronic Enteropathy Clinical Activity Index (CCECAI), depending on the individual study center. Summative histopathological scores and clinical activity were calculated for each tissue (stomach, duodenum, ileum, and colon) and each tissue histologic score (inflammatory/morphologic feature). The correlation between CCECAI/CIBDAI and summative histopathologic score was significant ( P < .05) for duodenum ( r = 0.42) and colon ( r = 0.33). In evaluating the relationship between histopathologic scores and clinical activity, significant ( P < .05) correlations were observed for crypt dilation ( r = 0.42), lamina propria (LP) lymphocytes ( r = 0.40), LP neutrophils ( r = 0.45), mucosal fibrosis ( r = 0.47), lacteal dilation ( r = 0.39), and villus stunting ( r = 0.43). Compared to earlier grading schemes, the simplified scoring system shows improved utility in correlating histopathologic features (both summative histology scores and select histologic scores) to IBD clinical activity.

Treatment of inflammatory bowel disease (IBD) in dogs and cats

2011 ◽  
Vol 14 (1) ◽  
pp. 165-171 ◽  
Author(s):  
K. Malewska ◽  
A. Rychlik ◽  
R. Nieradka ◽  
M. Kander
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Clinical Symptoms ◽  
Activity Index ◽  
Disease Activity Index ◽  
Immunosuppressive Drugs ◽  
Clinical Activity ◽  
Aminosalicylic Acid ◽  
Probiotic Treatment ◽  
Inflammatory Bowel

Treatment of inflammatory bowel disease (IBD) in dogs and catsThe treatment of inflammatory bowel disease (IBD) possesses numerous difficulties owing to the unclear etiology of the disease. This article overviews the drugs used in the treatment of IBD depending on the intensity of clinical symptoms (Canine Inflammatory Bowel Disease Activity Index and Canine Chronic Enterophaty Clinical Activity Index). Patients demonstrating mild symptoms of the disease are usually placed on an appropriate diet which may be combined with immunomodulative or probiotic treatment. In moderate progression of IBD, 5-aminosalicylic acid (mesalazine or olsalazine) derivatives may be administered. Patients showing severe symptoms of the disease are usually treated with immunosuppressive drugs, antibiotics and elimination diet. Since the immune system plays an important role in the pathogenesis of the disease, the advancements in biological therapy research will contribute to the progress in the treatment of canine and feline IBD in the coming years.

Effects of probiotic bacteria on mucosal polyamines levels in dogs with IBD and colonic polyps: a preliminary study

2018 ◽  
Vol 9 (2) ◽  
pp. 247-255 ◽  
Author(s):  
G. Rossi ◽  
M. Cerquetella ◽  
S. Scarpona ◽  
G. Pengo ◽  
K. Fettucciari ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Caspase 3 ◽  
Cellular Proliferation ◽  
Activity Index ◽  
Clinical Activity ◽  
High Concentration ◽  
Ki 67 ◽  
Inflammatory Bowel ◽  
Anti Inflammatory

Spermine (SPM) and its precursor putrescine (PUT), regulated by ornithine decarboxylase (ODC) and diamino-oxidase (DAO), are polyamines required for cell growth and proliferation. Only a few studies have investigated the anti-inflammatory and tumour inhibitory properties of probiotics on mucosal polyamine levels. We investigated the effects of a high concentration multistrain probiotic for human use on colonic polyamine biosynthesis in dogs. Histological sections (inflammatory bowel disease, n=10; polyposis, n=5) were assessed after receiving 112 to 225×109 lyophilised bacteria daily for 60 days at baseline (T0) and 30 days after treatment end (T90). Histology scores, expression of PUT, SPM, ODC and DAO, and a clinical activity index (CIBDAI) were compared at T0 and T90. In polyps, cellular proliferation (Ki-67 expression), and apoptosis (caspase-3 protein expression) were also evaluated. After treatment, in inflammatory bowel disease significant decreases were observed for CIBDAI (P=0.006) and histology scores (P<0.001); PUT, SPM and ODC expression increased (P<0.01). In polyps, a significant decrease in polyamine levels, ODC activity, and Ki-67, and a significant increase in caspase-3 positivity and DAO expression (P=0.005) was noted. Our results suggest potential anti-proliferative and anti-inflammatory effects of the probiotic mixture in polyps and inflammation, associated with reduced mucosal infiltration and up-regulation of PUT, SPM, and ODC levels.

Sign in / Sign up

Export Citation Format

Share Document